Hansen Gwenn 4

What Happened
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NRIX), sold 5,394 shares in an open-market transaction on June 25, 2026. The shares were disposed at $20.00 each, for total proceeds of $107,880. This was a sale (not a purchase) and was executed under a pre-established Rule 10b5-1 trading plan, which typically schedules routine trades.

Key Details

• Transaction date and price: 2026-06-25 — 5,394 shares sold at $20.00/share.
• Total value: $107,880.
• Transaction type/code: Sale (S) — open market or private sale as reported.
• Shares owned after transaction: Not specified in the filing.
• Footnote: Transaction effected pursuant to a previously adopted Rule 10b5-1 trading plan.
• Filing timeliness: Report filed on 2026-06-25 (same date as transaction), no late filing indicated.

Context
A Rule 10b5-1 plan lets insiders execute pre-arranged trades at scheduled times; such sales are often routine and do not necessarily reflect new information about the company. For retail investors, purchases by insiders can be more indicative of confidence than routine sales, but disclosed sales are still useful to track as part of overall insider activity.